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Introduction: In small biopsies standard morphology cannot specifically subtype the tumor. Histologic
subtyping of lung cancer is mandatory for treatment. Immunohistochemical staining is a valuable tool
for diagnosis of lung cancer.
Aim: The aim of this study was to evaluate the diagnostic accuracy of minimal panel of Napsin A, CK 5/6
and CD 56 versus H&E of lung cancer in small biopsies.
Methods: 84 small sized tissue samples were obtained. Seventy samples were obtained via fiberoptic
bronchoscope (FOB) and 14 samples were obtained with transothoracic CT guided trucut needle. All sam-
ples were stained with H&E for morphologic diagnosis, then the same samples were stained with
immunohistochemical (IHC) staining including 3 antibodies (Napsin A, CK 5/6 and CD 56), then we com-
pared the diagnostic yield of both methods.
Results: After H&E staining, according to WHO 2004 classification: 40 cases were adenocarcinoma (AC),
10 were squamous cell carcinoma (SCC), 22 were large cell carcinoma (LCC) and 12 were neuroendocrine
tumors (NET). After IHC; 54 (64.3%) were AC, 11 (13.1%) were SCC, 11 (13.1%) were NET and 8 (9.5%) were
non small cell lung cancer not otherwise specified NSCLC NOS (Counterpart of large cell carcinoma in
2004 WHO classification). Napsin A was expressed in 98% (53/54) and CK 5/6 in 90.9% (10/11) of SCC.
CD 56 in 100% (11/11) of neuroendocrine tumors.
Conclusion: IHC with Napsin A, CK 5/6 and CD 56 has a more diagnostic value in precise typing of differ-
ent cell types of lung cancer than H&E in small biopsies.
 2016 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Lung cancer is one of the major causes of cancer deaths world-
wide. Lung cancer is the main cause of cancer death cases in men
as well as in women, lung cancer is the second leading cause of
death cases from cancer globally, following breast cancer [1].
In Egypt, according to The National Cancer Institute lung cancer
is the first cause of cancer related death cases in both gender [2].
Seventy percent of lung cancers are presented in advanced
stages and can’t be resected, small biopsy specimens remain the
main method of diagnosis for the majority of lung cancer patients
[3].Based on microscopic picture, main types are: Non-small cell
lung cancer (NSCLC), representing 85% of the patients. (NSCLC)
include types of squamous cell carcinoma, adenocarcinoma, and
large cell carcinoma [4] and small cell lung cancer (SCLC), account-
ing for about (15%) of the patients. Neuroendocrine tumors are also
included among main types of lung cancer.
Recently, classification of lung cancer especially the Non-small
variant found to be very important in the field of targeted therapy,
so accurate subtyping is important especially in small biopsy [3,5].
IASLC provided recommendation for the use of immune stains
as an aid to diagnosis, especially in tumors that do not show estab-
lished morphologic criteria by H&E stain [6]. Established morpho-
logical criteria are as follow: glandular differentiation or mucin for
adenocarcinoma, where the criteria for squamous cell carcinoma
are intercellular bridges and or keratinization. When all previous
established morphologic criteria absent, we do immunohistochem-
istry (see Table 1).iopsies,
Table 1
Detailed antigen retrieval methods and antibody dilution for each primary antibody.
Antigen Type Manufacturer Catalog Dilution Procedure Antibody
incubation
Antigen Retrieval
Napsin
A
Rabbit Polyclonal Cell MARQUE 352A-78 Ready to use 7 ml
prediluted
Manual Over night Heat induced epitope retrieval
(HIER)
CK5/6 Mouse
monoclonal
DAKO Clone D5/
16B4
Ready to use 6 ml Manual Over night Heat induced epitope retrieval
(HIER)
CD56 Mouse
monoclonal
DAKO Clone 123C3 Ready to use 6 ml Manual Over night Heat induced epitope retrieval
(HIER)
2 M.A.A. Rahman et al. / Egyptian Journal of Chest Diseases and Tuberculosis xxx (2016) xxx–xxxNapsin A is a lung-specific marker [7] as it is more sensitive and
specific than TTF-1 in diagnosis of lung adenocarcinoma [8]. The
diagnosis of SCC typically does not require the use of IHC tech-
niques. CK 5/6 is useful in diagnosis of SCC especially in the poorly
differentiated cell type [9,10].
CD56 is one of the most helpful neuroendocrine immunohisto-
chemical markers [11,12]. It’s the most sensitive marker for SCLC
[13].
The key immunohistochemical stains useful for SCLC diagnosis
including keratin, chromogranin, CD56, Ki-67, TTF-1 [14].Aim of the study
The aim of the study was to evaluate the diagnostic accuracy of
minimal panel of Napsin A, CK 5/6 and CD 56 versus H&E of lung
cancer in small biopsies.Table 2
Histologic subtype of lung cancer among the studied cases according to WHO 2004
classification of lung cancer (morphological diagnosis by H&E) (n = 84).
Types n %
ADC 40 47.6
Acinar pattern 9Materials and methods
Prospective case series study included 84 patients with lung
cancer; 70 cases were central tumors diagnosed with biopsies
obtained via FOB (pentax FB-18V or FB 19 TV) and 14 cases with
peripheral tumors diagnosed with transthoracic CT or ultrasound
guided biopsies.
All biopsies were formalin fixed paraffin embedded, processed
and from which 4-lm-thick sections were obtained and stained
by H&E then examined at pathology department, Faculty of medi-
cine, Mansoura university by 2 pathologists.
Immunostaining
For IHC staining, we routinely deparaffinized 4-m-thick sections
from paraffin block. The sections were incubated with 3% hydrogen
peroxide for 15 min to block endogenous peroxidase activity. We
used EDTA and citrate buffer. The sections were incubated over-
night at 37 C, and stained with a HRP (horseradish peroxidase)
method. The following antibodies were applied (Napsin-A–C
K5/6–CD56). We used 3-30-diaminobenzidine, harris hematoxylin
as the chromogen and counter stain, respectively.
Positive immunostaining for CD56 required 10% or more cells
with an intensity of at least 2+ on the relevant subcellular localiza-
tion [membranous for CD56/Neural Cell Adhesion Molecule
(NCAM)].
CK5/6 was considered positive for when it was cytoplasmic. For
Napsin A, stain was considered positive when it revealed cytoplas-
mic granularity.Solid pattern with mucin production 8
Papillary pattern 1
Non mucinous bronchioalveolar 2
Mucinous type bronchioalveolar 1
Mixed pattern 19
SCC 10 11.9
LCC 22 26.2
Neuroendocrine tumors Small Cell Carcinoma 10 14.3
Atypical carcinoid 2Statistics
Data were analyzed with SPSS version 16. The normality of data
was first tested with one-sample Kolmogorov-Smirnov test.
Qualitative data were described using number and percent.
Association between categorical variables was tested using Chi-Please cite this article in press as: M.A.A. Rahman et al., Role of minimal panel
Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.10.01square test. When 25% of the cells have expected count less than
5, Fisher exact test was used.
Continuous variables were presented as mean ± SD (standard
deviation). Analysis Of Variance (ANOVA test) used for comparison
of means of more than two groups.
Level significance
For all above mentioned statistical tests done, the threshold of
significance is fixed at 5% level (p-value).
The results were considered highly significant when the proba-
bility of error is less than 0.1% (p < 0.001).
Results
According to established morphologic criteria, adenocarcinoma
represented 47.6% of the cases (Table 2). However, after application
of immunostain adenocarcinoma was the most prevalent variant
among the histologic subtypes of lung cancer representing 64.3%
of the total cases (Table 3). It was found that adenocarcinoma rep-
resented 47.6% of the cases. The term NSCLC (NOS) was present
only in the IASLC 2011 classification and it is the counterpart to
large cell carcinoma to WHO 2004 classification.
After the application of immunostain, NSCLC (NOS) cases
decreased from 33.3–9.5% (Table 3).
Twenty eight cases initially diagnosed as NSCLC (NOS) where
established morphologic criteria of squamous cell carcinoma and
adenocarcinoma were absent. With application of three immunes-
tain (Napsin A, CK 5/6 and CD 56) the result were as follow: The
immuneprofile of nineteen cases was Napsin A +ve, CK 5/6 ve,
CD 56 ve. So, diagnosis changed to NSCLC favour adenocarci-
noma. One Case was Napsin A ve, CK 5/6 +ve, CD 56 ve. So, diag-
nosis changed to NSCLC favour squamous cell carcinoma (Photo 2).
Eight cases were Napsin A ve, CK 5/6 ve, CD 56 ve. So, the
diagnosis remained NSCLC (NOS).
Thirteen cases were initially diagnosed as solid predominant
adenocarcinoma and stained with Napsin A and CK 5/6. The results
were as follow: Twelve cases were Napsin A +ve, CK 5/6 ve and
one case was Napsin A ve, CK 5/6 ve with positive internal con-immunostaining in accurate diagnosis of lung cancer using small biopsies,
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Table 3
Histologic subtypes of tumors after
immunostaining with Napsin A, CK5/6,
CD56 (n = 84) (According to IASLC 2011).
Tumor Cell Types n (%)
ADC 54(64.3)
SCC 11 (13.1)
NSCL (NOS) 8 (9.5)
Neuroendocrine tumors 11 (13.1)
Bold value represented that number of
adenocarcinoma cases was the biggest
number.
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squamous cell carcinoma and the diagnosis was confirmed to be
adenocarcinoma.
Five cases were diagnosed morphologically as papillary pre-
dominant adenocarcinoma. We applied TTF-1 and Napsin A to
the previous five cases. All these cases were Napsin A +ve, TTF1
+ve. TTF1 was added to exclude papillary variant of renal cell
carcinoma.
One case was diagnosed as micro papillary predominant adeno-
carcinoma and it was stained with Napsin A and TTF1 to exclude
metastatic ovarian tumor as the case was female. This case was
Napsin A +ve and TTF1 +ve.
Sixteen cases were diagnosed as well differentiated adenocarci-
noma (fourteen acinar predominant variant, two lepidic predomi-
nant variant). All of these cases stained with Napsin A and they
were positive (Photo 1). Change in diagnosis of adenocarcinoma
after immunohistochemistry is illustrated in (Table 4).
Five cases morphologically diagnosed as moderate squamous
cell carcinoma. They all stained with Napsin A and CK 5/6. Napsin
A was added to exclude squamoid variant of adenocarcinoma. Four
cases were Napsin A ve, CK 5/6 +ve, confirming diagnosis of squa-
mous cell carcinoma. One case was Napsin A +ve, CK 5/6 ve so
diagnosis changed to NSCLC favour adenocarcinoma.
Neuroendocrine tumors
Twelve cases are morphologically diagnosed as neuro-
endocrine tumors nine cases were small cell carcinoma, two cases
were atypical carcinoid and 1 case as suspected neuroendocrine
tumor (there was no definite pattern can be identify).
To prove neuroendocrine features among nine cases of small
cell carcinoma we used CD56 alone and it was positive in six cases
(Photo 3). All previous six cases were having small hyperchromatic
nuclei, scanty cytoplasm and extensive necrosis. For the remaining
three cases the immuneprofile was as follow: For two cases, in
addition to CD56 we added CK5/6 as there was sheeting of tumorA
Photo 1. Acinar predominant adenocarcinoma: A) H&E shows tumor cells consists of ro
Strong intensity staining of tumor cells for napsin A, ImmunoPeroxidase-DAB x400.
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was negative while CD56 was positive, so the diagnosis was con-
firmed. For the Last case which was crushed, we added Napsin A,
CK5/6 to exclude poorly differentiated adenocarcinoma and small
cell variant of SCC and were negative while CD56 was positive con-
firming small cell carcinoma.
In the two cases diagnosed morphologically as atypical carci-
noid in these cases there were areas formed of crushed cells, one
case was CD56 +ve/Napsin A ve where Napsin A was added to
exclude poorly differentiated ADC. The other case was CD56 +ve/
CK5/6 ve where CK5/6 was added to exclude small cell variant
of SCC and it was negative, CK7 was done and it was positive, we
couldn’t determine the mitotic count in the two small biopsy spec-
imens, so Ki-67 score was low in cases of TC and AC while it was
very high in Large Cell Neuroendocrine Carcinoma LCNEC and SCLC
cases. In the previous two cases, the mitotic index was very high
(>80%) so the diagnosis changed to Non small cell lung cancer with
neuroendocrine morphology NSCLC NEM possible LCNEC (Photo 4).
Immunohistochemical panel for diagnosis of neuroendocrine
tumors (According to IASLC 2011) is illustrated in (Table 5).
Napsin A is mandatory for diagnosis of adenocarcinoma. CK5/6
is mandatory for diagnosis of squamous cell carcinoma. CD56 is
mandatory for diagnosis of neuroendocrine tumors (Table 4).Discussion
Lung cancer is one of the most common cancer. Seventy percent
of patients are presented in advanced stage, so small biopsy remain
the main method of diagnosis [3].
Immunohistochemistry has a major role in accurate diagnosis
and precise typing of different pulmonary tumors.
The use of the three antibodies is done in this work aiming to
minimize the term NSCLC – NOS on small samples providing as
specific a histologic classification as possible to facilitate treatment
approach of medical oncologist (Mok et al., 2009 & Boyle and Levin,
2008) [17,18].
In this study adenocarcinoma was the commonest subtype in
young male and this was in coordination with Zander and Farver,
2008 [15].
In this study histologic subtypes of lung cancer among the stud-
ied cases according to WHO 2004 classification of lung cancer were
as follow: adenocarcinoma represent 47.6% (83.3% female, 37.9%
male), NSCLC was 26.2%, while Squamous cell carcinoma was
11.9% (13.6% male, 5.5% female), Neuroendocrine tumors represent
14.3% (Small cell carcinoma 11.9% and 2.3% atypical carcinoma)
and this is different from that reported by Travis et al., 2004 [16].
As regarding subtypes of lung cancer after application of recom-
mendation of IASLC 2011 classification of lung cancer and by use of
immunohistochemistry results were as follows: ADC: 64.3%, NSCLB
und to oval-shaped malignant glands separated by desmoplastic reaction x200. B)
immunostaining in accurate diagnosis of lung cancer using small biopsies,
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A B
Photo 2. A case of NSCLC(NOS) proved to be squamous cell carcinoma. A) H&E shows malignant cells with abundant cytoplasm, vesicular nuclei and marked atypia x200. B)
Positive cytoplasmic staining of tumor cells for ck5/6 ImmunoPeroxidase-DAB x400. C,D) Negative staining of tumor cells for both napsin A and CD56 respectively
ImmunoPeroxidase-DAB x200.
Table 4
Change in diagnosis of adenocarcinoma after immunohistochemistry.
All cases n = 54 Solid Acinar Papillary Lepidic Micro papillary
1 stain Napsin A +ve 14 2
Napsin A ve
2 stains Napsin A +ve – CK5/6 ve 12
Napsin A ve – CK5/6 –ve
Napsin A +ve – TTF1 +ve
1 5 1
3 stains Napsin A +ve – CK5/6 ve – CD56 ve 19
A B
Photo 3. A case of small cell carcinoma. A) H&E showing malignant round to fusiform cells growing in sheets and nests. The nuclei appears ovoid with moulding and
hyperchromasia x400. B) Positive cytoplasmic staining of tumor cells for CD56 tumor cells (score 3) Immunoperoxidase-DAB x400.
A B
Photo 4. A case Non small cell lung carcinoma with neuroendocrine morphology possible large cell neuroendocrine carcinoma (NSCLC with NEM possible NCLEC). A) H&E
solid pattern of tumor growth morphologically similar to Photo 1 x400. However by doing immunostains proved the following: B) Positive cytoplasmic staining of tumor cells
for CD56Immunoperoxidase-DAB x/200.
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Table 5
Immunohistochemical panel for diagnosis of neuroendocrine tumors (According to IASLC 2011).
Final diagnosis Napsin A CK 5/6 CD 56
+ve ve +ve ve +ve ve
SCLC (9 cases) 6
2 2
1 1 1
NSCLC with NEM possible LCNEC (2 cases) 1 1
1 1
SCLC, small cell lung carcinoma; NSCLC with NEM possible LCNEC, Non-small cell lung carcinoma with neuroendocrine morphology possible large cell neuroendocrine
carcinoma.
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cinoma was the most common subtype of lung cancer representing
64.3% of the total cases.
The increasing number of adenocarcinoma cases may be due to
the increase of the cases of (Non small cell lung carcinoma favour
adenocarcinoma) after use of immunostain and this goes with
other reports. This was in agreement with Righiet al., 2011 whose
work revealed the increased number of adenocarcinoma cases after
the use of immunestain on FNAC samples initially diagnosed as
NSCLC NOS.
Non small cell lung carcinoma favour adenocarcinoma (NSCLC
favour ADC) was a diagnostic category when lacking classic fea-
tures of adenocarcinoma. We diagnosed 14 cases after using of
Napsin A antibody [6].
Although adenocarcinoma is still a morphological diagnosis but
the variant (NSCLC favour ADC) need the panel done in this study
[6].
In the squamous cell carcinoma either well or moderate cases
we are not in need to do immunohistochemistry. However in mod-
erate differentiated squamous cell carcinoma cases, we combined
Napsin A with CK5/6 to exclude squamoid variant of adenocarci-
noma. Robert et al., 2007 [20] mentioned the Pivotal rule of
CK5/6 as differentiating marker between squamous cell carcinoma
and adenocarcinoma [21,22]. This was in agreement with Kargi
et al., 2007 who mentioned that CK 5/6 seem to be useful for differ-
entiating AC and SCLC from SCC with 89% specificity and 79%
sensitivity.
The category Non Small Cell Lung carcinoma favour squamous
cell carcinoma is diagnosed only by using immunohistochemistry.
This was in agreement with Kaufmann et al. 2001 [19]. Where it is
mentioned that CK5/6 can be used to identify poorly differentiated
and undifferentiated carcinoma that are typical for squamous cell
carcinoma [6]. This where tumor by H&E lacking classic features
of squamous cell carcinoma.
As regard neuroendocrine tumors diagnosis of small cell carci-
noma not needed immunohistochemistry, however we applied
CD56 to confirm neuroendocrine features and to exclude small cell
variant of squamous cell carcinoma, lymphoma and other blue
round cell tumor. This recommendations was mentioned by other
reports [23].
As a whole, immunohistochemical stains should be interpreted
with caution especially in the setting of markedly crushed biopsy
with otherwise un interpretable morphology. Neuroendocrine
markers such as chromogranin and synaptophysin and neuron
specific enolase (NSE) may stain some NSCLC cases. CD56 held
more promise as a specific neuroendocrine marker and it stained
all cases of small cell carcinoma. This was in agreement with
Travis, 2010 [24].
The diagnosis of LCNEC is difficult to establish based on small
biopsies or cytology. This is related to difficulty to do immunohis-
tochemistry and to detect neuroendocrine pattern in such small
biopsy. For these reasons we had 2 cases diagnosed as atypical car-
cinoid morphologically and we stained them by Ki-67 whichPlease cite this article in press as: M.A.A. Rahman et al., Role of minimal panel
Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.10.01revealed more than 80% labeling so the diagnosis changed to
LCNEC [12,24].
So we used an algorithm the term of NSCLC (NOS) as little as
possible. The percent decreased from 25.9% to 9.4% after immuno-
histochemistry and this in contrary to Travis et al., 2011. This dif-
ference due to small number of the cases applied [3]. This in
contrary to Rigih et al., in whose work the cases of NSCLC NOS
reduced from 36% before immunestain to 14% after immunestain.
Conclusion
Immunohistochemistry has a valuable role in precise typing
and differentiation of different pulmonary tumors. There’s a need
to improve WHO 2004 classification that depend on H&E using
multidisciplinary approach.
We used Napsin A, CK56 & CD56 as minimal panel in order to
reach accurate typing and final diagnosis aiming at good response
with chemotherapy.
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